Pharsight

Xenleta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6753445 NABRIVA Pleuromutilin derivatives having antibacterial activity
Jul, 2021

(2 years ago)

US8153689 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Mar, 2028

(3 years from now)

US8071643 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Jan, 2029

(4 years from now)

US9120727 NABRIVA Process for the preparation of pleuromutilins
May, 2031

(6 years from now)

Xenleta is owned by Nabriva.

Xenleta contains Lefamulin Acetate.

Xenleta has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Xenleta are:

  • US6753445

Xenleta was authorised for market use on 19 August, 2019.

Xenleta is available in solution;intravenous, tablet;oral dosage forms.

Xenleta can be used as treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms.

Drug patent challenges can be filed against Xenleta from 19 August, 2028.

The generics of Xenleta are possible to be released after 23 May, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 19, 2024
Generating Antibiotic Incentives Now(GAIN) Aug 19, 2029

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEFAMULIN ACETATE ingredient

NCE-1 date: 19 August, 2028

Market Authorisation Date: 19 August, 2019

Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms

Dosage: SOLUTION;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

XENLETA family patents

Family Patents